DE69133576D1 - Verfahren zur Herstellung von Enantiomerisch reine Beta-D-Dioxolan-Nukleoside - Google Patents

Verfahren zur Herstellung von Enantiomerisch reine Beta-D-Dioxolan-Nukleoside

Info

Publication number
DE69133576D1
DE69133576D1 DE69133576T DE69133576T DE69133576D1 DE 69133576 D1 DE69133576 D1 DE 69133576D1 DE 69133576 T DE69133576 T DE 69133576T DE 69133576 T DE69133576 T DE 69133576T DE 69133576 D1 DE69133576 D1 DE 69133576D1
Authority
DE
Germany
Prior art keywords
enantiomerically pure
preparation
nucleosides
pure beta
dioxolane nucleosides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69133576T
Other languages
English (en)
Other versions
DE69133576T2 (de
Inventor
Chung K Chu
Raymond F Schinazi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Georgia
Emory University
University of Georgia Research Foundation Inc UGARF
Original Assignee
University of Georgia
Emory University
University of Georgia Research Foundation Inc UGARF
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Georgia, Emory University, University of Georgia Research Foundation Inc UGARF filed Critical University of Georgia
Publication of DE69133576D1 publication Critical patent/DE69133576D1/de
Application granted granted Critical
Publication of DE69133576T2 publication Critical patent/DE69133576T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
DE69133576T 1990-12-05 1991-12-05 Verfahren zur Herstellung von Enantiomerisch reine Beta-D-Dioxolan-Nukleoside Expired - Lifetime DE69133576T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US622762 1990-12-05
US07/622,762 US5179104A (en) 1990-12-05 1990-12-05 Process for the preparation of enantiomerically pure β-D-(-)-dioxolane-nucleosides

Publications (2)

Publication Number Publication Date
DE69133576D1 true DE69133576D1 (de) 2007-09-13
DE69133576T2 DE69133576T2 (de) 2008-04-17

Family

ID=24495427

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69133576T Expired - Lifetime DE69133576T2 (de) 1990-12-05 1991-12-05 Verfahren zur Herstellung von Enantiomerisch reine Beta-D-Dioxolan-Nukleoside

Country Status (9)

Country Link
US (1) US5179104A (de)
EP (4) EP1600448A3 (de)
JP (3) JP3421335B2 (de)
AT (1) ATE368660T1 (de)
AU (2) AU9147591A (de)
CA (2) CA2590125A1 (de)
DE (1) DE69133576T2 (de)
ES (1) ES2291268T3 (de)
WO (1) WO1992010497A1 (de)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6903224B2 (en) 1988-04-11 2005-06-07 Biochem Pharma Inc. Substituted 1,3-oxathiolanes
US6175008B1 (en) 1988-04-11 2001-01-16 Biochem Pharma Inc. Processes for preparing substituted 1,3-oxathiolanes with antiviral properties
US6350753B1 (en) * 1988-04-11 2002-02-26 Biochem Pharma Inc. 2-Substituted-4-substituted-1,3-dioxolanes and use thereof
US5466806A (en) * 1989-02-08 1995-11-14 Biochem Pharma Inc. Processes for preparing substituted 1,3-oxathiolanes with antiviral properties
US6703396B1 (en) 1990-02-01 2004-03-09 Emory University Method of resolution and antiviral activity of 1,3-oxathiolane nuclesoside enantiomers
US5914331A (en) * 1990-02-01 1999-06-22 Emory University Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane
US6069252A (en) * 1990-02-01 2000-05-30 Emory University Method of resolution and antiviral activity of 1,3-oxathiolane nucleoside enantiomers
US5276151A (en) * 1990-02-01 1994-01-04 Emory University Method of synthesis of 1,3-dioxolane nucleosides
US5204466A (en) * 1990-02-01 1993-04-20 Emory University Method and compositions for the synthesis of bch-189 and related compounds
US5444063A (en) * 1990-12-05 1995-08-22 Emory University Enantiomerically pure β-D-dioxolane nucleosides with selective anti-Hepatitis B virus activity
US5925643A (en) 1990-12-05 1999-07-20 Emory University Enantiomerically pure β-D-dioxolane-nucleosides
US5817667A (en) * 1991-04-17 1998-10-06 University Of Georgia Research Foudation Compounds and methods for the treatment of cancer
GB9111902D0 (en) * 1991-06-03 1991-07-24 Glaxo Group Ltd Chemical compounds
US20050192299A1 (en) * 1992-04-16 2005-09-01 Yung-Chi Cheng Method of treating or preventing hepatitis B virus
GB9226927D0 (en) * 1992-12-24 1993-02-17 Iaf Biochem Int Dideoxy nucleoside analogues
JPH09504785A (ja) * 1993-09-10 1997-05-13 エモリー、ユニバーシティー 抗ｂ型肝炎ウイルス活性を有するヌクレオシド
US20020120130A1 (en) * 1993-09-10 2002-08-29 Gilles Gosselin 2' or 3' -deoxy and 2', 3' -dideoxy-beta-L-pentofuranonucleo-side compounds, method of preparation and application in therapy, especially as anti- viral agents
US5587362A (en) * 1994-01-28 1996-12-24 Univ. Of Ga Research Foundation L-nucleosides
IL115156A (en) * 1994-09-06 2000-07-16 Univ Georgia Pharmaceutical compositions for the treatment of cancer comprising 1-(2-hydroxymethyl-1,3-dioxolan-4-yl) cytosines
US5703058A (en) 1995-01-27 1997-12-30 Emory University Compositions containing 5-fluoro-2',3'-didehydro-2',3'-dideoxycytidine or a mono-, di-, or triphosphate thereof and a second antiviral agent
US6391859B1 (en) 1995-01-27 2002-05-21 Emory University [5-Carboxamido or 5-fluoro]-[2′,3′-unsaturated or 3′-modified]-pyrimidine nucleosides
US5808040A (en) * 1995-01-30 1998-09-15 Yale University L-nucleosides incorporated into polymeric structure for stabilization of oligonucleotides
ES2276404T3 (es) 1995-06-07 2007-06-16 Emory University Nucleosidos con actividad antivirus de la hepatitis-b.
US5753789A (en) * 1996-07-26 1998-05-19 Yale University Oligonucleotides containing L-nucleosides
US6022876A (en) * 1996-11-15 2000-02-08 Yale University L-β-dioxolane uridine analogs and methods for treating and preventing Epstein-Barr virus infections
US5792773A (en) * 1996-11-15 1998-08-11 Yale University L-β-dioxolane uridine analog administration for treating Epstein-Barr virus infection
WO1998041522A1 (en) * 1997-03-19 1998-09-24 Emory University Synthesis, anti-human immunodeficiency virus and anti-hepatitis b virus activities of 1,3-oxaselenolane nucleosides
EP1380303B1 (de) 1998-11-02 2008-09-17 Gilead Sciences, Inc. Kombinationstherapie zur Behandlung von Hepatitis B Infektionen
BR9916849A (pt) 1998-12-23 2001-10-30 Shire Biochem Inc Análogos de nucleosìdeos antivirais
US6511983B1 (en) 1999-03-01 2003-01-28 Biochem Pharma Inc. Pharmaceutical combination of antiviral agents
US6653318B1 (en) * 1999-07-21 2003-11-25 Yale University 5-(E)-Bromovinyl uracil analogues and related pyrimidine nucleosides as anti-viral agents and methods of use
CA2389745C (en) 1999-11-04 2010-03-23 Shire Biochem Inc. Method for the treatment or prevention of flaviviridae viral infection using nucleoside analogues
US6436948B1 (en) 2000-03-03 2002-08-20 University Of Georgia Research Foundation Inc. Method for the treatment of psoriasis and genital warts
DK1574512T3 (da) * 2001-03-01 2008-03-03 Abbott Lab Polymorfe og andre krystallinske former af cis-FTC
BR0317113A (pt) * 2002-12-09 2005-10-25 Univ Georgia Res Found Timina dioxolano e combinações para uso contra cepas resistentes a 3tc/azt de hiv
NZ540728A (en) 2003-01-14 2008-08-29 Gilead Sciences Inc Compositions and methods for combination antiviral therapy
DE10335061B4 (de) * 2003-07-31 2005-11-17 Wacker-Chemie Gmbh Verfahren zur Herstellung von OH-geschützten [4-(2,6-damino-9H-purin-9-yl)-1,3-dioxolan-2-yl]methanol-Derivaten
CA2554782C (en) * 2004-02-03 2013-08-13 Emory University Methods to manufacture 1,3-dioxolane nucleosides
TWI375560B (en) 2005-06-13 2012-11-01 Gilead Sciences Inc Composition comprising dry granulated emtricitabine and tenofovir df and method for making the same
TWI471145B (zh) 2005-06-13 2015-02-01 Bristol Myers Squibb & Gilead Sciences Llc 單一式藥學劑量型
WO2009052050A1 (en) * 2007-10-15 2009-04-23 Pharmasset, Inc. Dioxolane thymine phosphoramidates as anti-hiv agents
CN102325783A (zh) 2008-12-23 2012-01-18 法莫赛特股份有限公司 嘌呤核苷的合成
CA2748034A1 (en) 2008-12-23 2010-07-01 Pharmasset, Inc. Purified 2'-deoxy'2'-fluoro-2'-c-methyl-nucleoside-phosphoramidate prodrugs for the treatment of viral infections
PA8855601A1 (es) 2008-12-23 2010-07-27 Forformidatos de nucleósidos
BR112012015120B1 (pt) 2009-12-22 2020-07-21 Bridgestone Corporation composição de modificador de vinila melhorada e processos para a utilização da mesma
SG184323A1 (en) 2010-03-31 2012-11-29 Gilead Pharmasett Llc Stereoselective synthesis of phosphorus containing actives
CN103351414B (zh) * 2013-06-19 2016-06-01 河南中烟工业有限责任公司 烟用保润剂1-o-羟乙基-d-吡喃甘露糖及其制备方法
WO2015005961A1 (en) 2013-07-12 2015-01-15 Emd Millipore Corporation A method of determining virus removal from a sample containing a target protein using activated carbon

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ228645A (en) 1988-04-11 1991-09-25 Iaf Biochem Int 1,3-dioxolane derivatives substituted in the 5th position by a purine or pyrimidine radical; treatment of viral infections
US5041449A (en) * 1988-04-11 1991-08-20 Iaf Biochem International, Inc. 4-(nucleoside base)-substituted-1,3-dioxolanes useful for treatment of retroviral infections
US5047407A (en) * 1989-02-08 1991-09-10 Iaf Biochem International, Inc. 2-substituted-5-substituted-1,3-oxathiolanes with antiviral properties
US5276151A (en) * 1990-02-01 1994-01-04 Emory University Method of synthesis of 1,3-dioxolane nucleosides
GB9103544D0 (en) * 1991-02-20 1991-04-10 Alcan Int Ltd Coating powders

Also Published As

Publication number Publication date
JP2001097973A (ja) 2001-04-10
EP1600448A2 (de) 2005-11-30
AU1664097A (en) 1997-07-17
EP1164133A3 (de) 2002-01-02
AU714646B2 (en) 2000-01-06
AU9147591A (en) 1992-07-08
JP2007008959A (ja) 2007-01-18
EP1164133B1 (de) 2007-08-01
EP1600448A3 (de) 2006-08-23
JP3421335B2 (ja) 2003-06-30
EP1164133A2 (de) 2001-12-19
ES2291268T3 (es) 2008-03-01
JP3881165B2 (ja) 2007-02-14
EP1693373A1 (de) 2006-08-23
DE69133576T2 (de) 2008-04-17
JPH07502973A (ja) 1995-03-30
CA2099589A1 (en) 1992-06-06
WO1992010497A1 (en) 1992-06-25
EP0562009A4 (en) 1993-11-24
JP4280276B2 (ja) 2009-06-17
EP0562009A1 (de) 1993-09-29
US5179104A (en) 1993-01-12
CA2590125A1 (en) 1992-06-25
ATE368660T1 (de) 2007-08-15
CA2099589C (en) 2007-08-21

Similar Documents

Publication Publication Date Title
DE69133576D1 (de) Verfahren zur Herstellung von Enantiomerisch reine Beta-D-Dioxolan-Nukleoside
FI931708A0 (fi) Herbicida substituerade aryl-haloalkylpyrazoler
DE3889393T2 (de) Verfahren zur Herstellung von 2,2,6,6-Tetramethyl-4-piperidylaminen.
DE59100830D1 (de) Verfahren zur Herstellung von 3-Aminomethyl-3,5,5,-trimethyl-cyclohexylamin.
DE59300243D1 (de) Verfahren zur Herstellung von 3,5-Difluoranilin.
DE69113695T2 (de) Verfahren zur Herstellung von Perfluoralkoxysulfonverbindungen.
DE3889524D1 (de) Methode zur Stabilisierung von eingesättigten Organosilicium-Zusammensetzungen.
DE59004613D1 (de) Verfahren zur Herstellung von substituierten 2-Chlorpyridinen.
DE69300551T2 (de) Verfahren zur Herstellung von (3R,4R)-3-Hydroxy-4-Hydroxymethyl-4-Butanolid.
DE59309150D1 (de) Verfahren zur Herstellung von E,Z-Butendial-bis-dialkylacetalen
DE3851306D1 (de) Verfahren zur Herstellung von optisch-aktiven 1,2-Diolen.
DE69210069T2 (de) Verfahren zur Herstellung von 1,3-Dioxolen
DE59200298D1 (de) Verfahren zur Herstellung von 2,4-Dichlorfluorbenzol.
ATE6255T1 (de) Verfahren zur herstellung von 2,3,5trichlorpyridin.
DE3887212D1 (de) Verfahren zur Herstellung von Derivaten von 6,7-Diazyl-7-desacetylforskolin.
DE59103040D1 (de) Verfahren zur Herstellung von symmetrischen 2,2'-Methylen-bis-benztriazolylphenolen.
DE59104649D1 (de) Verfahren zur Herstellung von N,N,N',N'-Tetraglycidyl-3,3'-dialkyl-4,4'-diaminodiphenylmethanen.
DE69107897T2 (de) Verfahren zur Herstellung von N,N'-bis(tetrabromophthalimid).
DE59106016D1 (de) Verfahren zur Herstellung von 2,3-Dihydrobenzofuranen.
DE59104221D1 (de) Verfahren zur Herstellung von 2,3,5-Trimethyl-p-benzochinon.
DE59203827D1 (de) Verfahren zur Herstellung von 2,2-Bis-hydroxymethyl-butandiol-(1,4).
ATE123488T1 (de) Verfahren zur herstellung von benzolsulfonamiden.
DE3881103T2 (de) Verfahren zur Herstellung von 1,3,2-Oxazaphosphorinan.
DE59203617D1 (de) Verfahren zur Herstellung von 2,4-Dichlor-5-fluorbenzonitril.
ATE6502T1 (de) Verfahren zur herstellung von n-(1'alkoxycarbonyl[thyl)-2,6-dialkylanilinen.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition